Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation by Agnew, Emma et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucocorticoids, antenatal corticosteroid therapy and fetal heart
maturation
Citation for published version:
Agnew, EJ, Ivy, J, Stock, S & Chapman, K 2018, 'Glucocorticoids, antenatal corticosteroid therapy and fetal
heart maturation' Journal of molecular endocrinology. DOI: 10.1530/JME-18-0077
Digital Object Identifier (DOI):
10.1530/JME-18-0077
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of molecular endocrinology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 07. Jul. 2018
Glucocorticoids and fetal heartE J Agnew et al.Journal of Molecular 
Endocrinology
R61–R7361 1:
REVIEW
Glucocorticoids, antenatal corticosteroid 
therapy and fetal heart maturation
Emma J Agnew1,*, Jessica R Ivy1, Sarah J Stock2 and Karen E Chapman1
1University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, UK
2MRC Centre for Reproductive Health, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, UK
Correspondence should be addressed to K E Chapman: Karen.Chapman@ed.ac.uk
*(E J Agnew is now at Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA)
Abstract
Glucocorticoids are essential in mammals to mature fetal organs and tissues in order 
to survive after birth. Hence, antenatal glucocorticoid treatment (termed antenatal 
corticosteroid therapy) can be life-saving in preterm babies and is commonly used in 
women at risk of preterm birth. While the effects of glucocorticoids on lung maturation 
have been well described, the effects on the fetal heart remain less clear. Experiments 
in mice have shown that endogenous glucocorticoid action is required to mature the 
fetal heart. However, whether the potent synthetic glucocorticoids used in antenatal 
corticosteroid therapy have similar maturational effects on the fetal heart is less clear. 
Moreover, antenatal corticosteroid therapy may increase the risk of cardiovascular 
disease in adulthood. Here, we present a narrative review of the evidence relating to the 
effects of antenatal glucocorticoid action on the fetal heart and discuss the implications 
for antenatal corticosteroid therapy.
Introduction
Through most of gestation, the mammalian fetus is 
maintained in a low glucocorticoid environment, with 
fetal glucocorticoid concentrations typically five- to ten-
fold lower than maternal. As birth approaches, fetal plasma 
glucocorticoid concentration rises dramatically. This is 
essential for survival once born. Without glucocorticoid 
action, the lungs, heart and other organs and tissues 
are immature at birth, resulting in neonatal death 
(Fowden et  al. 1998). Preterm birth (prior to 37  weeks 
completed gestation) occurs before this physiological 
rise in endogenous glucocorticoids. Hence, antenatal 
corticosteroid therapy (ACT) – in which a potent synthetic 
glucocorticoid, betamethasone or dexamethasone, is 
administered to women at risk of preterm delivery – is 
widely used to mature the fetal lungs. This aims to reduce 
neonatal morbidity and improve survival of preterm 
babies. However, whether ACT faithfully mimics the 
effects of endogenous glucocorticoids on the maturation 
of other fetal organs, including the heart, is currently 
unclear. Crucially, less than half of ACT administered 
prior to preterm birth is optimally timed, and around 50% 
of women who receive ACT go on to deliver at or near 
term (Razaz et al. 2015, Makhija et al. 2016, Grzeskowiak 
et al. 2017) (reviewed in Kemp et al. 2016). Given evidence 
associating excessive prenatal glucocorticoid exposure 
with long-term adverse cardiovascular consequences 
(Fowden et al. 2016), it is important to establish exactly 
how fetal glucocorticoids – either endogenous or 
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exogenous – ‘programme’ cardiovascular health in later 
life. This knowledge is essential to allow an informed 
analysis of the benefits and harms resulting from ACT and 
to refine the use of ACT during pregnancy.
Endogenous glucocorticoids and 
fetal maturation
The adrenal gland is the site of synthesis and release of 
corticosteroid hormones: mineralocorticoids and the 
glucocorticoids, cortisol and corticosterone (cortisol 
predominates in most mammals, whereas rats and 
mice produce only corticosterone). In human embryos, 
the adrenal cortex is discernible from the eighth week 
of gestation, though the morphology differs from the 
adult (Mesiano & Jaffe 1997). Prior to birth, the fetal 
zone (comprising most of the adrenal cortex) is the 
major site of steroidogenesis. The definitive zone starts 
to produce mineralocorticoids in late gestation, whereas 
the transitional zone produces cortisol, transitioning 
into the zona fasciculata, the site of glucocorticoid 
production, from late gestation (Mesiano & Jaffe 1997). 
De novo synthesis of cortisol from cholesterol initiates 
in the human fetal adrenal gland around the 28th 
week of gestation (Mastorakos & Ilias 2003), but plasma 
glucocorticoid concentrations remain low until the week 
before birth (Fowden et al. 1998). Similarly, in fetal mice, 
plasma glucocorticoid concentrations are low during 
early-to-mid-gestation then increase rapidly following 
initiation of adrenal steroidogenesis at embryonic day 
(E) 14.5 (Michelsohn & Anderson 1992), approximately 
5 days before birth. The low glucocorticoid environment 
during gestation is maintained by at least two placental 
mechanisms: 11β-hydroxysteroid dehydrogenase (11β-
HSD)-2, which converts active cortisol and corticosterone 
into their intrinsically inert 11-keto-metabolites (Chapman 
et al. 2013) and P-glycoprotein-mediated active retrograde 
transport of glucocorticoids from fetus to mother, 
maintaining the feto–maternal glucocorticoid gradient in 
both endogenous and exogenous glucocorticoids (Varma 
1986, Fowden & Forhead 2004, Walker et al. 2017). 11β-
HSD2 is also widely expressed in the fetus during early-
to-mid-gestation, to ‘mop-up’ any glucocorticoid that 
reaches sensitive tissues, particularly the brain (Wyrwoll 
et al. 2011, 2015). In late gestation, placental 11β-HSD-2 
activity markedly declines (Brown et al. 1996, Murphy & 
Clifton 2003) and maternal glucocorticoid concentrations 
rise, coincident with increased fetal production of 
glucocorticoids (Mastorakos & Ilias 2003). Together, these 
generate the dramatic rise in fetal plasma glucocorticoid 
concentrations close to term. These increased 
concentrations of endogenous glucocorticoids act, via 
glucocorticoid receptor (GR), to mature the fetal lungs 
(Jobe & Ikegami 2000, Bird et al. 2015) and other organs, 
in order to survive in the extra-uterine environment after 
birth. Mice with global knockout of GR die shortly after 
birth with immature and severely impaired lung function 
(Cole et  al. 1995). A proportion of GR knockout mice 
die earlier, in late gestation, with immature and poorly 
functional hearts (Rog-Zielinska et  al. 2013), suggesting 
cardiac immaturity contributes to perinatal mortality and 
morbidity with deficiency in glucocorticoid action.
ACT: a life-saving therapy
In high-income countries, and increasingly in low- and 
middle-income countries, antenatal corticosteroids (24 mg 
betamethasone or dexamethasone, administered over 
48 h) are routinely administered to women considered at 
imminent risk of preterm delivery (birth prior to 37 weeks 
gestation and before the natural increase in endogenous 
glucocorticoid concentrations would be expected). 
Antenatal corticosteroids are widely accepted to be the 
most effective therapy to reduce neonatal morbidity 
and mortality in preterm infants born between 24 and 
34 weeks gestation: ACT reduces the incidence of neonatal 
death and the incidence and severity of respiratory 
distress syndrome, cerebral haemorrhage and necrotising 
enterocolitis (Roberts et al. 2017). Thus, in high-income 
settings, antenatal corticosteroids are undoubtedly life-
saving in preterm infants delivered at 24–34  weeks of 
gestation within a 2- to 7-day window following initiation 
of a single course of ACT. However, the safety and efficacy of 
ACT in other settings have been called into question: most 
notably in low- and middle-income settings, following 
multiple courses of ACT, in late preterm infants (born at 
34–37 weeks of gestation) and where birth occurs outside 
the 2- to 7-day window following steroid administration 
(reviewed in Kemp et al. 2016). The latter is a particular 
concern in high-income settings where estimates suggest 
50–80% of pregnant women that receive ACT remain 
undelivered at 7  days after treatment (McPheeters et  al. 
2005, Razaz et  al. 2015), and 50% actually go on to 
deliver their babies at or near term (Razaz et  al. 2015) 
(reviewed in Kemp et al. 2016). This suggests widespread 
over-treatment with antenatal corticosteroids resulting 
in unnecessary and inappropriately timed corticosteroid 
exposure in babies, many of which subsequently deliver 
at term. Similar concerns surround the use of repeat 
courses of ACT, administered when birth does not occur 
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within 7  days of the first course and preterm delivery 
remains likely (McKinlay et al. 2015b, Kemp et al. 2016). 
There are potential short-term and long-term adverse 
effects associated with unnecessary or inappropriately 
timed corticosteroid treatment. Delivery later than 
7 days after a single course of ACT is associated with an 
increased risk of perinatal death and maternal infection 
(McLaughlin et  al. 2003). Some follow-up studies have 
demonstrated adverse neurodevelopmental effects in 
children born preterm or exposed to multiple courses of 
ACT (Asztalos et al. 2014, Crowther et al. 2016). Whether 
ACT affects risk of cardiovascular disease in humans 
remains unclear (Dalziel et al. 2005, de Vries et al. 2008, 
McKinlay et  al. 2015a). However, cardiovascular disease 
can take decades to manifest, and it may yet be too early 
to fully assess the risk in adults. Nevertheless, excessive 
or mistimed exposure to glucocorticoids in utero is widely 
acknowledged to have detrimental long-term adverse 
effects in animals, including non-human primates, that 
increase the risk of cardiovascular and/or metabolic 
disease in adulthood (Seckl & Holmes 2007, Rog-Zielinska 
et al. 2014). The mechanisms remain to be fully elucidated, 
but undoubtedly include long-term adverse effects on the 
heart and vasculature.
Maturation of the heart, before and 
after birth
In the time shortly before and continuing after birth, 
the heart undergoes extensive growth and remodelling, 
driven by cardiomyocyte hyperplasia and associated 
with structural, functional and biochemical maturation. 
These remarkable changes are driven by mechanical and 
hormonal factors and are crucial for survival following 
birth. They also set the foundation for later life, and, 
importantly, influence the risk of developing heart 
disease in adulthood. Increased cardiac load stimulates 
fetal myocyte proliferation (Sedmera et  al. 2003, 
Drenckhahn 2009). The fetal heart needs to pump against 
the resistance of the placental vascular bed with the 
resulting haemodynamic forces being important drivers 
of cardiac maturation. The complexity of the fetal part 
of the placental vasculature increases through branching 
morphogenesis, though exactly how this influences fetal 
haemodynamics is currently unclear. In sheep, fetal 
hypertension promotes cardiomyocyte proliferation prior 
to terminal differentiation. Conversely, reduced systolic 
load reduces cardiomyocyte proliferation and, thus, fetal 
heart weight (reviewed in Thornburg et al. 2011). However, 
placental insufficiency, with high placental impedance 
against pulsatile flow, also impairs myocardial maturation 
(Thornburg et  al. 2010); the mechanism remains to be 
fully elucidated.
Fetal systolic and diastolic functions improve before 
and shortly after birth, with increasing maturation of the 
contractile and relaxation properties of cardiomyocytes 
(Harada et al. 1997, Corrigan et al. 2010). It is proliferation 
of differentiated mononuclear diploid cardiomyocytes 
that increases heart mass in late gestation and early after 
birth in mice and sheep (Soonpaa et  al. 1996, Porrello 
et al. 2011, Alkass et al. 2015, Jonker et al. 2015). The very 
limited evidence available is consistent with a similar 
capacity for cardiomyocyte proliferation in neonatal 
human hearts (Mollova et  al. 2013). Beyond the first 
postnatal week in mice, cardiomyocyte proliferation is 
negligible, and increases in heart mass occur through 
cardiomyocyte hypertrophy following binucleation 
and terminal differentiation of cardiomyocytes. Any 
subsequent proliferation that occurs is restricted to rare 
mononucleated diploid cardiomyocytes (Patterson et  al. 
2017). Structural changes that occur in cardiomyocyte 
maturation during the neonatal period include increased 
myofibril density and organisation, maturation 
of mechanical and electrical coupling between 
cardiomyocytes and the appearance of binucleated cells. 
This latter is associated with a wave of DNA synthesis that 
occurs in mouse cardiomyocytes between postnatal day 
P4 and P7 (Soonpaa et al. 1996). Additionally, as perinatal 
cardiomyocytes mature, some nuclei become polyploid. In 
mice, increases in ploidy account for all cell-cycle activity 
following P13 (Brodsky et al. 1980, Alkass et al. 2015). The 
majority of murine cardiomyocyte nuclei are diploid, with 
only 10% being polyploid (Adler et  al. 1996). Similarly, 
in humans, most cardiomyocyte nuclei are diploid up to 
7 years of age (though higher levels of ploidy are observed 
following childhood cardiac disease) (Brodsky et  al. 
1994). Glucocorticoids play a vital role in the normal 
maturational changes that occur in cardiomyocytes before 
birth. The extent to which endogenous glucocorticoids 
directly affect cardiac maturation in the neonate remains 
unclear. Even more unclear is how ACT affects these 
maturational processes in heart structure and function, 
both before and after birth.
Glucocorticoid action in the fetal heart
Glucocorticoids bind to intracellular receptors: the 
glucocorticoid receptor (GR or type II receptor) and the 
high-affinity mineralocorticoid receptor (MR or type 
I receptor). In mineralocorticoid target tissues, MR is 
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co-expressed with 11β-HSD2, conferring mineralocorticoid 
specificity upon MR (Chapman et  al. 2013). However, 
in certain MR-expressing tissues in which 11β-HSD2 
is not co-expressed, most notably the heart and the 
hippocampus, MR is activated by cortisol/corticosterone. 
Moreover, because of its high affinity, cardiac MR is 
likely to be occupied even at the glucocorticoid nadir. 
Importantly, while betamethasone and dexamethasone 
(the synthetic glucocorticoids commonly used in ACT) 
potently activate GR, they are mineralocorticoid sparing, 
showing little activation of MR (we return to this below). 
Ligand-bound GR and MR translocate to the nucleus 
where they are active as transcription factors, triggering 
cascades of gene expression (Coutinho & Chapman 2011).
Glucocorticoids, through GR, promote structural, 
functional and metabolic remodelling in mouse fetal 
cardiomyocytes (Rog-Zielinska et  al. 2013, 2015). Mice 
with global GR knockout have small and immature hearts 
that function poorly. The E/A wave ratio, a marker of 
cardiac maturity, is reduced in GR knockout mice and early 
systolic and diastolic function are impaired (Rog-Zielinska 
et  al. 2013), similar to the preterm heart (reviewed in 
Rog-Zielinska et  al. 2014). This functional immaturity 
goes hand-in-hand with structural immaturity (short and 
disorganised myofibrils, a lack of cardiomyocyte alignment 
in the outer ventricle wall) and biochemical immaturity 
(calcium handling, energy metabolism). Endogenous 
glucocorticoids directly impact cardiomyocytes. SMGRKO 
mice, with GR deficiency restricted to cardiomyocytes and 
vascular smooth muscle cells (VSMCs), replicate much of 
the cardiac phenotype of global GR knockout mice (Rog-
Zielinska et  al. 2013). SMGRKO mice have immature 
systolic function in late gestation, associated with short 
and disorganised myofibril structure (Rog-Zielinska et al. 
2013). This is underpinned by reduced expression of genes 
encoding structural proteins myosin heavy chain (MHCα) 
and proteins vital for calcium handling (SERCA2, RYR2) 
and energy metabolism in late gestation (Rog-Zielinska 
et al. 2013).
Not all the actions of endogenous glucocorticoids 
upon the fetal heart are direct. The use of a cardiomyocyte-
specific approach avoids the perturbation of blood pressure 
and suppression of the hypothalamic–pituitary–thyroid 
(HPA) axis associated with exogenous glucocorticoid 
administration. While SMGRKO mice reproduce much 
of the cardiac phenotype of global GR-knockout mice, 
some aspects differ. In contrast to global GR knockout 
mice, SMGRKO mice have normal-sized hearts, a normal 
E/A-wave ratio and normal cardiac expression of Nppa 
(encoding atrial natriuretic peptide, ANP) (Rog-Zielinska 
et al. 2013). This suggests that these deficits in the global 
knockout mice are attributable to lack of GR elsewhere 
than in cardiomyocytes and VSMC. Hemodynamic 
forces may account for at least some of these differences. 
Fetal ANP responds to volume stimuli and regulates 
blood pressure (Cameron & Ellmers 2003). The normal 
cardiac expression of ANP in SMGRKO fetuses suggests 
blood pressure is normal (as it is in adult SMGRKO 
mice (Richardson et  al. 2017)). Glucocorticoids exert 
powerful pressor effects, including in the fetus (Unno 
et  al. 1999, Forhead & Fowden 2004). Indeed, adrenal 
insufficiency is likely to be a factor in the haemodynamic 
instability that is common in preterm infants and which 
contributes to morbidity and mortality (Ng et  al. 2004, 
Ibrahim et  al. 2011). The non-cardiac sites for these 
important hemodynamic effects are currently unclear, 
though the fetal and placental vasculature are candidates. 
Antenatal dexamethasone treatment in rats dramatically 
reduces the extent and complexity of the vasculature 
within the labyrinth zone (the site of feto–maternal 
exchange), causing intrauterine growth restriction (IUGR) 
(Hewitt et al. 2006). In pregnant mice, corticosterone or 
dexamethasone treatment (at doses sufficient to cause 
IUGR) reduce placental vascularisation if administered 
in mid-gestation (E11–16) but not if administered from 
E14–E19, the time when glucocorticoid concentrations 
naturally rise in mice (Vaughan et al. 2012, 2013). Excessive 
glucocorticoid concentrations may also impact feto–
placental vasculature in humans. In pregnant women, 
repeat courses of ACT starting at gestational ages ranging 
from 27 to 32  weeks impaired the normal gestational 
increase in villous capillarisation (Elfayomy & Almasry 
2014). Similarly, glucocorticoid usage in pregnant women 
with asthma was associated with reduced fetal capillary 
length and volume (Mayhew et al. 2008). Given the crucial 
role of the placental vasculature in cardiac development 
(Thornburg et  al. 2010), glucocorticoids very likely 
contribute to fetal cardiac maturation via effects on feto–
placental vasculature. Support for this idea comes from a 
recent study in Hsd11b2−/− mice, a model of antenatal GC 
excess and IUGR. Hsd11b2−/− mice show abnormal cardiac 
maturation, with impaired heart function in late gestation 
(Wyrwoll et  al. 2016). This is associated with restricted 
growth of fetal vessels in the placenta and reduced 
umbilical vein blood velocity (Wyrwoll et al. 2009, 2016). 
Restoration of the normal placental vasculature and blood 
flow restored normal heart function in Hsd11b2−/− mice 
(Wyrwoll et al. 2016).
The mechanisms by which glucocorticoids mature 
fetal cardiomyocytes have been investigated in vitro. 
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Treatment of mouse fetal cardiomyocytes with either 
dexamethasone or corticosterone for 24 h promotes their 
structural, functional and biochemical maturation (Rog-
Zielinska et  al. 2015). GR targets in these cells include 
a number of transcription factors (Rog-Zielinska et  al. 
2015), supporting a cascade effect of GR activation. 
In vivo and in vitro dexamethasone rapidly induces PGC-
1α, a critical regulator of cardiac mitochondrial capacity 
and vital for the functional and metabolic maturation 
of the fetal heart (Lai et al. 2008). Knockdown of PGC-
1α in fetal cardiomyocytes abolished the glucocorticoid 
effects on mitochondrial O2 consumption and 
myofibril structure, suggesting it is a key mediator of 
glucocorticoid-induced maturation of cardiomyocyte 
structure and mitochondrial capacity (Rog-Zielinska 
et  al. 2015). Whether PGC-1α mediates other aspects 
of glucocorticoid-induced cardiomyocyte maturation 
is unknown. However, PGC-1α knockdown in human 
embryonic stem cell-derived cardiomyocytes decreased 
mitochondrial content and activity (as expected) and 
also reduced concentrations of reactive oxygen species 
(ROS) and heightened vulnerability to metabolic stress 
(Birket et  al. 2013). This suggests that glucocorticoids, 
via PGC-1α might increase ROS production in maturing 
cardiomyocytes. Other primary targets of GR in fetal 
cardiomyocytes include Ppara, Klf15 and Lipin1 (Rog-
Zielinska et al. 2015). This points to a direct role for GR 
in promoting the capacity of cardiomyocytes for fatty 
acid oxidation as the preferred substrate for cardiac 
mitochondrial ATP generation, consistent with the 
increase in cardiac ATP concentration and ATP delivery 
to myofibrils induced by dexamethasone administration 
in late gestation rats (Tsuzuki et al. 2009, Mizuno et al. 
2010). Other rapidly induced targets of GR in primary 
fetal mouse cardiomyocytes include Dio2, encoding 
deiodinase (D2) the enzyme that converts thyroxine 
(T4) into the more biologically active thyroid hormone, 
T3 (Rog-Zielinska et  al. 2015). Thus, amplification of 
intracellular thyroid hormone action is part of the cascade 
of events initiated by GR activation and is consistent 
with evidence that at least some of the effects of the 
prepartum increase in glucocorticoids are mediated via 
T3 (Forhead & Fowden 2014). Indeed, cortisol increases 
plasma availability of T3 in the fetus by inducing hepatic 
expression of D1 (responsible for producing most of the 
circulating T3), and downregulates placental clearance of 
T3 by the D3 enzyme (Forhead & Fowden 2014, Jonker 
& Louey 2016). Many of the actions of glucocorticoid 
and thyroid hormones during fetal and neonatal heart 
maturation overlap. Both accelerate the switch from 
MHC-β to MHC-α and both increase ANP (van Tuyl et al. 
2004, Chattergoon et al. 2012a) (these are indirect effects 
in the case of glucocorticoids (Rog-Zielinska et al. 2015)). 
In vivo, haemodynamic forces are changed by both 
glucocorticoids and thyroid hormones. Like synthetic 
glucocorticoids (Rog-Zielinska et  al. 2014), in vitro and 
possibly in vivo, T3 is anti-proliferative in cardiomyocytes, 
promoting the switch to hypertrophic growth and 
increasing the population of terminally differentiated 
binucleated myocytes (Chattergoon et al. 2007, 2012a,b). 
If GR is precociously activated before the HPA axis has 
started to produce circulating fetal thyroid hormones in 
any substantial amount, this could limit maturation of fetal 
organs by glucocorticoids. This may be more important 
in rodents (where fetal thyroid hormone synthesis only 
initiates in late gestation) than in humans or in sheep 
models, where thyroid hormone synthesis occurs by mid-
gestation (Forhead & Fowden 2014). Interestingly, while 
dexamethasone alone is ineffective in human induced 
pluripotent cell (iPSC)-derived cardiomyocytes, it acts 
in concert with T3 to improve the electrophysiology, 
bioenergetics and contractile force generation of the cells 
(Birket et al. 2015). Both T3 and dexamethasone are also 
required for T-tubule development in human iPSC-derived 
cardiomyocytes (Parikh et al. 2017). This inter-dependent 
relationship of thyroid hormone and glucocorticoids in 
cardiac maturation is an important consideration for 
ACT, where only glucocorticoid is administered.
The transition to neonatal life: a role for 
glucocorticoids in cardiac adaption?
The transition to extra-uterine life is accompanied by 
loss of the placenta, a low-resistance vascular bed. In 
term birth, the associated circulatory changes rapidly 
increase peripheral resistance in the systemic circulation, 
with greater cardiac afterload and systemic arterial 
pressure. Blood and tissue oxygenation rapidly increase 
(partial pressure of oxygen in arterial blood increases 
over two-fold), as do plasma glucose and free fatty acid 
concentrations, to fuel the increased energy needs (Jonker 
& Louey 2016). Endogenous glucocorticoids are likely 
to be critical in facilitating these adaptions, although 
apart from metabolic effects, their role has been little 
explored. Interestingly, expression profiling and in silico 
transcription factor analysis in sheep heart across the 
perinatal period suggests glucocorticoids transiently 
suppress immune responses at birth and that they support 
metabolic changes during the transition from fetal to 
neonatal life (Richards et al. 2015).
https://doi.org/10.1530/JME-18-0077
http://jme.endocrinology-journals.org © 2018 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.
R66E J Agnew et al. Glucocorticoids and fetal heart 61 1:Journal of Molecular 
Endocrinology
In mice, cell-cycle arrest in cardiomyocytes 
occurs shortly after birth and is triggered by increased 
mitochondrial ROS production and oxidative DNA 
damage following birth (Puente et  al. 2014). Transient 
hyperoxia in neonatal mice exacerbates oxidative DNA 
damage and accelerates cell-cycle arrest, whereas hypoxia 
has the opposite effect. Only hypoxia alters (increases) 
the heart-to-body weight ratio (Puente et  al. 2014). 
Reduced cell number with hyperoxia is compensated 
by cardiomyocyte hypertrophy. Transient hyperoxia 
in neonatal rats causes left ventricular hypertrophy 
in adulthood and increases vulnerability to pressure 
overload, with severe heart failure in those exposed to 
transient high O2 at birth (Bertagnolli et  al. 2014). The 
mechanism was not explored, but reduced cardiomyocyte 
endowment as a result of premature cell-cycle exit, is 
associated with pathological cardiac hypertrophy in 
adult rats (Porrello et  al. 2009). Glucocorticoids may 
promote this process: in neonatal rats, administration of 
dexamethasone from P1 to P3 decreased cardiomyocyte 
proliferation and increased binucleation at P4, with a 
reduction in cardiomyocyte number and an increase 
in heart/body weight ratio (presumably as a result of 
cardiomyocyte hypertrophy) apparent by 2 weeks of age 
(Gay et al. 2015). Dexamethasone induces oxidative stress 
in neonatal rat hearts (Adler et al. 2010). Whether this is 
mediated through PGC-1α will be interesting to establish, 
given the role of PGC-1α in mitochondrial ROS production 
in human embryonic stem cell-derived cardiomyocytes 
(Birket et  al. 2013). Deletion of GR in cardiomyocytes/
VSMC increases cardiomyocyte proliferation in neonatal 
mice and increases heart weight, without associated 
cardiomyocyte hypertrophy (Richardson et al. 2017). This 
is consistent with GR activation normally restraining 
cardiomyocyte number in neonatal mice. Glucocorticoid 
activation of cardiac MR may have the opposite effect. 
At subpressor doses, cortisol stimulates cardiomyocyte 
proliferation in fetal sheep without affecting binucleation 
(Giraud et  al. 2006). This hyperplastic effect can be 
blocked by intra-pericardial antagonism of MR (Feng et al. 
2013). Similarly, spironalactone antagonism of MR from 
birth reduced adult heart weight in mice, independently 
of cardiomyocyte GR (Richardson et  al. 2017). This is 
consistent with endogenous glucocorticoid action via MR 
being pro-proliferative in perinatal cardiomyocytes.
The heart in preterm infants
Preterm birth occurs before the organs have had sufficient 
time to accrue mass, and when they are structurally and 
functionally immature. Thus, in preterm infants, heart 
mass (relative to body weight) is reduced at birth (Aye et al. 
2017). Moreover, if driven by cardiac load, oxygenation 
and arterial pressure, then terminal differentiation of 
cardiomyocytes will likely occur in the same time scale in 
the preterm heart as in the term. In an important recent 
study, hearts from preterm infants who died 1–42  days 
following birth were compared with appropriately grown 
stillborn infants (20–40 weeks of gestation). Birth per se 
reduced markers of cardiomyocyte proliferation compared 
to age-matched stillborns (Bensley et al. 2018). Therefore, 
preterm birth prompts the cessation of cardiomyocyte 
proliferation, plausibly as a result of the oxygen-induced 
DNA damage discussed above (Puente et  al. 2014). This 
potentially reduces cardiomyocyte endowment in preterm 
infants compared to the term-born infants, resulting 
in maladaptive structural remodelling in the neonatal 
period. Alterations in cardiac geometry and mechanics are 
already apparent in the preterm-born infant and child (Lee 
et al. 1992, Aye et al. 2017). The reduced heart mass after 
preterm birth becomes normalised by disproportionate 
cardiac hypertrophy and increased left ventricular mass 
in subsequent ‘catch-up’ growth in the early postnatal 
period (Kozak-Barany et  al. 2001, Aye et  al. 2017), with 
differences in cardiac structure and function persisting 
in adulthood (reviewed in Bensley et  al. 2016, Le et  al. 
2018). Preterm-born adults show increased left ventricular 
mass (independent of blood pressure), thickened 
ventricular walls and displaced apex (Lewandowski 
et  al. 2013). Studies in preterm lambs demonstrate that 
catch-up growth occurs by cardiomyocyte hypertrophy: 
cardiomyocyte volume is increased despite no differences 
in absolute or relative heart weight (Bensley et al. 2010). 
Similarly, in hypoplastic mouse hearts, myocardial mass 
is normalised by accelerated cardiomyocyte hypertrophy 
(Drenckhahn et al. 2015). Thus, myocyte hypertrophy can 
compensate for fewer cardiomyocytes to maintain mass. 
However, in the very and extremely preterm infant, the 
reduction in cardiomyocyte number may be too great for 
this compensatory mechanism to normalise heart size: 
left ventricular mass is reduced in adults born extremely 
preterm (Kowalski et al. 2016) and in children born very 
preterm (Mohlkert et al. 2018).
Ontogenetically determined cardiomyocyte number 
(or endowment) is an important factor in vulnerability 
to cardiac disease (Levkau et  al. 2008). In a large study 
of over 2.6 million individuals born in Sweden between 
1987 and 2012, gestational age prior to 32  weeks at 
delivery was strongly associated with risk of heart failure 
in childhood and early adulthood. The risk was increased 
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17-fold in those born at <28 weeks and 4-fold if born at 
28–31 weeks of gestation (Carr et al. 2017). This suggests 
a vulnerability to heart failure with preterm birth, with 
a reduced threshold at which an insult will trigger 
heart failure. Reduced cardiomyocyte endowment with 
compensatory hypertrophy may explain this vulnerability, 
with subsequent greater stress on individual myocytes. 
Stress and/or ageing is associated with polyploidy in 
cardiomyocyte nuclei (Anatskaya et al. 2009, Senyo et al. 
2013). Polyploidy may be a mechanism to allow larger 
cardiomyocytes to fulfil metabolic and functional demands 
(Schoenfelder & Fox 2015). In humans, polyploidy is 
likely to arise in childhood and is strongly associated with 
impaired cardiac function and pathological hypertrophy 
(Brodsky et al. 1991, 1994). Whether preterm hearts show 
higher levels of ploidy is unknown. However, myocyte 
ploidy is increased in preterm sheep (Bensley et al. 2010) 
consistent with polyploidy as an indicator of greater 
susceptibility to cardiac stress/load in the preterm-born 
adult. Fibrosis, seen in adults born preterm, may occur 
secondarily to cardiomyocyte loss.
ACT: what are we doing to the heart?
Although preterm birth is strongly associated with 
increased risk of cardiovascular disease in later life, the 
evidence to date suggests that effects of preterm birth 
on cardiac morphology and function are independent 
of antenatal corticosteroid exposure (Dalziel et al. 2005, 
Aye et  al. 2017). While both are predicted to have 
similar effects (e.g. reduced cardiomyocyte endowment, 
cardiomyocyte hypertrophy), ACT is likely to be a minor 
contributor compared to preterm birth itself. Indeed, 
should preterm birth occur, in the short term, ACT 
may enhance cardiomyocyte function directly through 
rapid effects on metabolic and structural maturation 
and possibly indirectly by improving haemodynamic 
stability. Glucocorticoids increase haemodynamic load in 
the fetus as well as the neonate (Unno et al. 1999), likely 
to affect cardiomyocyte proliferation and/or maturation 
independently of direct effects of glucocorticoids in 
cardiomyocytes. Indeed, systemic haemodynamic 
instability (hypotension and low systemic blood flow) 
is inversely related to gestational age at birth (du Plessis 
2009) and is a cause of mortality in some preterm infants 
(Ng et al. 2004, Kluckow 2005, Sehgal 2011, Rog-Zielinska 
et  al. 2014). In fetuses >29  weeks gestational age, heart 
rate was rapidly (within 24 h) and transiently decreased 
following betamethasone (Mulder et  al. 2004). This was 
ascribed to the baroreceptor reflex in which an increase 
in blood pressure very rapidly triggers a decrease in 
heart rate, causing blood pressure to fall. This did not 
occur in younger fetuses (Mulder et al. 2004). Thus, ACT 
has gestational age-specific effects on the developing 
fetus, consistent with the idea of developmental 
windows of susceptibility to the maturational effects of 
glucocorticoids, including in the heart, dependent on the 
stage of organ development at the time of glucocorticoid 
exposure: organogenesis, growth or maturation. This 
warrants further research.
Of concern, around half of women exposed to a 
single course of ACT do not deliver their babies within 
the optimal 2- to 7-day time window (Kemp et  al. 
2016). If delivered more than 7  days after a single 
course of ACT, the risk of perinatal death is increased 
two-fold and neonatal death three-fold (McLaughlin 
et  al. 2003). The reasons may be multi-factorial, but 
studies in sheep support the idea that heart function is 
compromised by excessive glucocorticoid exposure in 
utero. A modest but chronic maternal hypercortisolaemia 
in late gestation sheep altered the trajectory of myocyte 
maturation and increased expression of calcium 
signalling genes (Richards et al. 2014), consistent with a 
short-term benefit. However, continuation of maternal 
hypercortisolaemia to term resulted in a high incidence 
of stillbirth (Keller-Wood et al. 2014). This was associated 
with reduced cardiac mitochondrial number and function 
and increased cardiac expression of hypoxia-response 
genes, though not the hypoxia master regulators, HIF1α 
or ARNT themselves (Richards et  al. 2014). Chronic 
maternal hypercortisolaemia also altered the fetal ECG 
and depressed aortic pressure and heart rate immediately 
prior to delivery (Antolic et  al. 2018). The authors 
speculate that glucocorticoid-induced alterations in fetal 
cardiac metabolism and/or ion homeostasis contribute 
to cardiac dysfunction, creating vulnerability to death 
during labour and/or delivery. In mice, a number of ion 
channels are direct targets of GR in fetal cardiomyocytes 
(Rog-Zielinska et al. 2015) and transgenic over-expression 
of GR in cardiomyocytes of adult mice causes ion-
channel remodelling (Sainte-Marie et al. 2007). MR over-
expression in cardiomyocytes also causes ion-channel 
remodelling (Ouvrard-Pascaud et  al. 2005). Teasing 
apart the relative contributions of GR and MR (and 
indeed, the balance between MR and GR (Richardson 
et  al. 2016)) to the complex effects of endogenous and 
exogenous glucocorticoids in the heart will be important 
in understanding how excessive glucocorticoid exposure 
in utero increases risk of perinatal death. Further research 
in this area is needed.
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There are longer-term concerns. The association 
between excessive exposure to glucocorticoid in utero 
(in term birth) and cardiovascular disease in adulthood 
is well known (Seckl & Holmes 2007). Indeed, excessive 
antenatal glucocorticoid exposure is considered as a key 
factor in the fetal origins of disease hypothesis (Seckl & 
Holmes 2007, Fowden & Forhead 2015, Fowden et  al. 
2016). It is, as yet, unclear if the short-term exposure to 
high concentrations of potent glucocorticoids used in 
ACT adversely affects the heart if birth does not occur 
within 7  days. We and others have reviewed a body 
of (sometimes conflicting) evidence from sheep and 
rodents suggesting glucocorticoid treatment reduces 
cardiomyocyte proliferation and promotes cardiomyocyte 
hypertrophy in the fetal and/or neonatal perinatal heart 
(Porrello et al. 2008, Rog-Zielinska et al. 2014, Richardson 
et  al. 2016), beneficial in the short-term in promoting 
heart function and survival, but possibly at the expense 
of adult cardiovascular resilience. As discussed earlier, 
cardiomyocyte endowment is a key factor in susceptibility 
to cardiac disease particularly in heart failure where 
cardiomyocyte loss contributes to development and 
progression of the disease (Rayment et al. 1999). People 
born at term who are exposed to excess glucocorticoids in 
utero may start life with fewer cardiomyocytes, contributing 
to risk of cardiovascular disease. More information on this 
vital question is required, in particular whether and how 
endogenous and exogenous glucocorticoids increase or 
reduce cardiomyocyte number at birth.
What are the effects of ACT upon endogenous 
glucocorticoid production and how might this affect the 
fetal and/or neonatal heart? Maternal stress, perinatal 
adversity and exposure to inappropriately timed or 
excessive concentrations of glucocorticoids prenatally are 
all associated with life-long alterations in HPA axis activity 
(Seckl & Holmes 2007, Waffarn & Davis 2012, Moisiadis 
& Matthews 2014). Relative adrenal insufficiency may 
occur in preterm neonates (especially if delivered prior 
to the initiation of de novo adrenocortical glucocorticoid 
synthesis at 28 weeks gestational age) or could result from 
ACT. The adrenal gland undergoes extensive remodelling 
immediately after term birth (Keene 1927) with regression 
of the fetal zone and maturation of the zona fasciculata. 
How this is affected in preterm infants and by ACT is 
unclear. However, what is clear is that both the maternal 
and the fetal HPA axis are suppressed following ACT 
(reviewed in Waffarn & Davis 2012). Corticosteroids 
administered in ACT persist in the fetal circulation for 
up to 3 days following the last dose (Ballard et al. 1975, 
Kajantie et  al. 2004, Nykanen et  al. 2007). However, 
cortisol concentration in the neonate remains depressed 
well after clearance of administered steroid from the 
circulation: a meta-analysis of 49 studies concluded that 
both basal cortisol and stress-induced cortisol release are 
suppressed in the preterm infant (Tegethoff et al. 2009). 
Furthermore, and while basal cortisol concentration 
recovers within 2 weeks of delivery, the cortisol response 
to pain is suppressed for at least 4  weeks and possibly 
considerably longer (Tegethoff et  al. 2009). In sheep, 
three courses of betamethasone reduced late gestation 
fetal cortisol concentration, which remained suppressed 
6 weeks postnatally (Li et al. 2013). Pituitary expression of 
POMC (encoding the precursor to ACTH) was reduced up 
to 12 weeks postnatally (Li et al. 2013). ACT also affects 
stress reactivity and HPA axis regulation in those infants 
who are delivered at or near term. In one study, newborns 
exposed to ACT but delivered near or at term were unable 
to mount a cortisol stress response, in contrast to non-
exposed newborns (Schaffer et al. 2009). On the other hand, 
another study reported an increase in stress reactivity of 
cortisol in term-born neonates after ACT exposure (Davis 
et  al. 2011). The reasons for the differences are unclear, 
but may relate to the conditions of testing or gestational 
age at ACT exposure. In an animal model, the ability of 
neonatal rats to mount a glucocorticoid response to stress 
depended on developmental age and was stressor specific 
(Walker 1991). HPA axis abnormalities persist: school-age 
children exposed to ACT but born at term had abnormal 
diurnal cortisol release: they lacked the normal cortisol 
awakening response and had a flattened diurnal rhythm 
in salivary cortisol concentration compared with non-
exposed term-born children (Edelmann et al. 2016).
These effects of ACT upon endogenous 
glucocorticoid production will have two consequences 
in the fetal and neonatal heart: First, in the short-term 
the HPA axis suppression will deprive cardiac MR of their 
glucocorticoid ligand. This will severely alter the cardiac 
MR/GR balance in favour of GR, for example, favouring 
the anti-proliferative effect of GR activation over the 
pro-proliferative effects of MR activation (Richardson 
et al. 2016). A similar consideration applies to MR in the 
hippocampus: here, the severe adverse psychological/
psychotic effects of dexamethasone in children treated 
for acute lymphoblastic leukaemia can be ameliorated by 
co-administration of cortisol, for replacement at the MR 
(Warris et al. 2016). Secondly, persistent suppression of 
the fetal HPA axis following ACT may also deprive GR as 
well as MR of stage-appropriate levels of its endogenous 
ligand. ACT, even in the term born, may therefore alter 
the trajectory of fetal and neonatal heart maturation 
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through changes in endogenous glucocorticoid 
production.
Concluding remarks
ACT is an established and effective therapy to improve 
lung function in preterm infants, to reduce neonatal 
morbidity and mortality. However, increasing evidence 
suggests it is not always harm-free, particularly in infants 
delivered at or near term (Althabe et  al. 2015). The 
jury is still out on whether ACT alters the risk of late-
onset cardiac disease, but given the complex effects of 
corticosteroids on haemodynamics and fetal and neonatal 
heart maturation, it would be surprising if it does not 
impact on the trajectory of perinatal heart maturation, 
subsequent cardiac growth and vulnerability to insult.
More knowledge is urgently needed to inform future 
refinements to ACT. Current treatment protocols were 
largely established decades ago and are based on limited 
knowledge regarding optimal formulation, timing of 
dosage and efficacy at different gestational ages. A ‘one 
size fits all’ dosage applies, irrespective of maternal 
weight or gestational age. It seems likely that different 
processes during cardiac development may be affected 
by ACT at different gestational ages. With the increasing 
use of ACT in preterm infants as young as 22 weeks, it is 
important to elucidate how glucocorticoids may impact 
heart structure and function at different times. The 
manner of cardiomyocyte proliferation shapes the heart. 
If ACT alters cardiomyocyte proliferation, particularly in a 
region-dependent manner, then both shape and function 
will be affected (Foglia & Poss 2016). There may be sex 
differences in cardiac susceptibility to ACT. Certainly 
evidence from sheep supports a sex difference in lung 
maturation, with a lower dose of betamethasone required 
for survival of female lambs compared to male (De Matteo 
et  al. 2010). Mice with GR knockout in cardiomyocytes 
show sex differences in cardiomyocyte hypertrophy 
(Richardson et  al. 2017) and in susceptibility to cardiac 
disease (Oakley et  al. 2013). Answers to these questions 
should help inform and refine future use of ACT.
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